Blog

 Malaria, a life-threatening infectious disease caused by the Plasmodium parasites and transmitted to humans by female Anopheles mosquitoes, today constitutes a major global health concern, despite a long history of progress in its prevention and treatment. The search for new therapeutic alternatives for this pervasive disease continues, and monoclonal antibodies (mAbs) are being seen as […]

 Malaria continues to be a global health concern. About 200 million cases of malaria disease and nearly 500,000 deaths were reported worldwide in 2013. Erad is a challenge, and control has been mostly through the use of antimalarial drugs that target Plasmodium, the parasites that cause malaria. Recently, there has been substantial progress, especially in

 The first thing a patient feels is a sigh of relief Monoclonal antibodies (mAbs) are a new therapeutic approach to malaria that could eliminate targeted therapy from the toolkit but vastly transform malaria treatment and prevention. The science behind monoclonal antibodies is complex but the details can be difficult to digest. This article highlights the

Malaria remains one of the most difficult global health problems. In 2020, there were an estimated 241 million cases of malaria worldwide, and approximately 627,000 people died from the disease. Consequently, this burden falls most heavily on sub-Saharan Africa, where nearly 95 percent of the global deaths from malaria occur. Over the past two decades,

Malaria continues to be a leading cause of death and disease globally, with hundreds of millions of cases and hundreds of thousands of deaths reported in a single year. Although tremendous strides have been made in the control and treatment of malaria, significant obstacles remain, particularly drug resistance and the lack of options for effective

 Today, malaria is still a global health problem. Despite major epidemiological studies being carried out, it still kills millions of people every year, mostly in sub-Saharan Africa. Research for the development of new, more effective drugs has led to a long list of treatments, from traditional remedies to sophisticated pharmaceutical interventions over the last decades.

Malaria, caused by Plasmodium parasites spread by Anopheles mosquitoes, remains a growing public health challenge around the world. This situation persists despite decades of research and development that have provided several measures to prevent and treat the disease. In light of this, the latest advancements in the field focus on the theory that a more

 Over the past 30 years, monoclonal antibodies (mAbs) have transformed the treatment landscape for many cancers and autoimmune and inflammatory diseases. Antibodies, which are large Y-shaped proteins, are now a vital weapon in modern medicine. Laboratory advances in their development are bringing us closer to the possibility of treating and preventing more difficult-to-control and deadly

 Malaria persists as a major global health challenge, with almost half of the world’s population at risk. This mosquito-borne disease is caused by so-called Plasmodium parasites, transmitted by Anopheles mosquitoes. Despite substantial progress achieved by anti-malarial prophylaxis and drug treatments, the emergence of drug-resistant strains, and the current limitations of available therapies, novel alternative approaches

 Malaria is still one of the most deadly diseases in the world and indeed one of the most deadly infectious diseases in sub-Saharan Africa. Despite dramatic improvements in the control of malaria in the last decades, which include the use of insecticide-treated bed nets, antimalarial drugs, and other vector-control strategies, the burden of malaria on